---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018580"
form_type: "8-K"
ticker: "HSDT"
cik: "0001610853"
company_name: "Solana Co"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:43:50.720655+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Helius Medical Q3 revenue $143K, net loss $3.7M; cash runway into Q2 2024

## Summary
- Q3 revenue $143K vs $196K YoY; decline due to PTAP expiration on June 30.
- Net loss $3.7M vs $1.0M; basic EPS loss $5.49 vs $2.90.
- Cash $6.6M plus $0.4M in warrant proceeds; operating burn $2.5M; runway into Q2 2024.
- Received UPC codes for PoNS system ($25,700) and mouthpiece ($7,900) from Medi-Span.
- Quebec MSSS LOI for up to 30 PoNS systems; UdeM order for 10 systems.

## SEC filing metadata
- accession: 0001558370-23-018580
- form_type: 8-K
- ticker: HSDT
- cik: 0001610853
- company_name: Solana Co
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610853/000155837023018580/0001558370-23-018580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610853/000155837023018580/hsdt-20231109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018580
- JSON: https://secwatch.observer/filing/0001558370-23-018580.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018580.txt

## Key facts
- Earnings Releases
  Solana Co reported the quarter ended September 30, 2023 results: revenue $143 thousand, net income Net loss was $3.7 million for the third quarter of 2023.
  - Period: the quarter ended September 30, 2023
  - Revenue: $143 thousand
  - Net income: Net loss was $3.7 million for the third quarter of 2023
  - Result: reported results
  source text: approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023. Third Quarter and Recent Business Updates ● Q3 2023 revenue of $143 thousand, compared to $196 thousand in Q3 2022, the decrease due to the expiration of the Patient Therapy Access Program (“PTAP”) on June 30, 2023. ● Operating cash burn of $2.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610853/000155837023018580/0001558370-23-018580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.